Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact ...

A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. Researchers analyzed peripheral ...

Covalent BTK inhibitors and Bcl-2 inhibitors are primary treatments for CLL, but alternatives are needed for relapsed or refractory cases. Treatment sequencing is vital, with potential switches ...

Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer Chronic lymphocytic leukemia (CLL) has unique epidemiologic, biologic, and clinical ...

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL). As treatment ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

People with chronic lymphocytic leukemia (CLL) may have a higher risk of developing skin cancers, such as melanoma, than those without CLL. They may also have less positive outlooks if they develop ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...